Evidence map›Paper›PMID 35357767›Full record

ArticleJournal of viral hepatitis2022

Low incidence and prevalence of hepatitis C in two cohorts of HIV pre-exposure prophylaxis adherence interventions in men who have sex with men in Southern California.

Adiba Hassan, Harold Glenn San Agustin, Leah Burke, Ryan Kofron, Katya Corado, Robert Bolan, Raphael J Landovitz, Michael P Dubé, Sheldon R Morris

2 registry-linked trialsOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of viral hepatitis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01761643 phase4completednot on this map

CCTG 595: A Multicenter, Randomized Study of Text Messaging to Improve Adherence to PrEP in Risky MSM

TypeinterventionalSponsorUniversity of California, San DiegoRan2012 to 2018Enrolled398ConditionsPatient Adherence, HIV SeronegativityArmsSoC + iTab
NCT01781806 phase4completednot on this map

A Pilot Demonstration Project to Operationalize Pre-exposure Prophylaxis as Part of Combination HIV Prevention Among Men Who Have Sex With Men (MSM) and Transgender Women in Los Angeles County

TypeinterventionalSponsorUniversity of California, Los AngelesRan2013 to 2016Enrolled328ConditionsHIV PreventionArmsemtricitabine 200mg/tenofovir 300mg
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Adiba HassanDepartment of Medicine, University of California, San Diego, California, USA.
Harold Glenn San AgustinDepartment of Medicine, University of Southern California, Los Angeles, California, USA.
Leah BurkeDepartment of Medicine, University of California, San Diego, California, USA.ORCID 0000-0001-8220-3263
Ryan KofronDepartment of Medicine, University of California, Los Angeles, California, USA.
Katya CoradoDivision of HIV Medicine, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA.
Robert BolanLos Angeles LGBT Center, Los Angeles, California, USA.
Raphael J LandovitzDepartment of Medicine, University of California, Los Angeles, California, USA.
Michael P DubéDepartment of Medicine, University of Southern California, Los Angeles, California, USA.
Sheldon R MorrisDepartment of Medicine, University of California, San Diego, California, USA.
University of California, Los Angeles · USUniversity of California San Diego · USUniversity of Southern California · USLos Angeles LGBT Center · USUCLA Medical Center · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Nina Thawata Harawa · 1997 to 2026
$53.5M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 1991 to 2018
$39.9M
NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR001881NIAID NIH HHS P30 AI028697NIMH NIH HHS P30 MH058107
6 · The paper itself

Abstract

HIV pre-exposure prophylaxis (PrEP) has been associated with incident hepatitis C virus (HCV) infection in men who have sex with men (MSM) due to decreased condom use. We examined rates of HCV among MSM and transgender women at high-risk of HIV on PrEP in Southern California using data from two trials (NCT01761643 and NCT01781806). Five of 599 participants (0.84%, 95% CI, 0.27-1.93) had HCV antibodies detected at entry. Factors associated with HCV seropositivity included being older (p = .002) and lower education level (p < .001). HCV-positive participants had no reported cases of sexually transmitted infection (rectal, urethral or pharyngeal gonorrhoea and/or chlamydia) at entry while HCV-negative participants had a prevalence of 18% (95% CI, 15%-21%). There were no significant differences in substance use and sexual risk behaviour between HCV-positive and HCV-negative participants 1-3 months prior to entry. Among early PrEP adopters, incident HCV did not occur despite ongoing condomless intercourse. Screening intervals for HCV in MSM on PrEP should be led by a risk behaviour assessment.

Indexed as

Hepatitis CHIV InfectionsPre-Exposure ProphylaxisSexual and Gender MinoritiesClinical Trials as TopicFemaleHepacivirusHomosexuality, MaleHumansIncidenceMalePrevalenceSexual Behaviorhepatitis CMSM (men who have sex with men)PrEP

Identifiers

PMID35357767
PMCPMC9908082
OpenAlexW4220929311

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.